8-K: Neumora Therapeutics Q1 2026 Results & Pipeline Update

Neumora Therapeutics reported Q1 2026 financial results, highlighting strong cash position and progress across key clinical programs, with several data readouts expected in H2 2026.

Summary

• Neumora Therapeutics announced its first quarter 2026 financial results and provided a business update.
• The company reported a net loss of $53.5 million for Q1 2026, an improvement from $68.0 million in Q1 2025.
• Research and development expenses decreased to $38.6 million in Q1 2026 from $52.2 million in Q1 2025.
• General and administrative expenses also decreased to $14.3 million in Q1 2026 from $18.8 million in Q1 2025.
• As of March 31, 2026, Neumora had $147.1 million in cash and cash equivalents.
• The company expects its current cash position to fund operations into the third quarter of 2027.
• Key pipeline highlights include the full enrollment of navacaprant KOASTAL-2 and -3 studies, with a joint topline data readout expected in Q2 2026.
• NMRA-511 for Alzheimer's disease agitation is on track to report data from a MAD expansion cohort in the second half of 2026, with a Phase 2 study anticipated in Q1 2027.
• NMRA-898 for schizophrenia is expected to report Phase 1 data in the second half of 2026.
• NMRA-215 for obesity is expected to enter the clinic in Q1 2027, with a program update in H2 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong pipeline progress and improved financial metrics, although the company remains in a loss-making phase typical for its stage.

Positives

• Strong cash position of $147.1 million as of March 31, 2026, expected to support operations into Q3 2027.
• Reduced net loss to $53.5 million in Q1 2026 from $68.0 million in Q1 2025.
• Decreased R&D expenses to $38.6 million in Q1 2026 from $52.2 million in Q1 2025.
• Decreased G&A expenses to $14.3 million in Q1 2026 from $18.8 million in Q1 2025.
• Full enrollment achieved in navacaprant KOASTAL-2 and -3 studies, with over 400 patients per study.
• Positive Phase 1b study results for NMRA-511 in Alzheimer's disease agitation, demonstrating an "unsurpassed clinical effect" and favorable safety profile.
• Multiple clinical programs advancing with data readouts and study initiations planned through 2027.

Negatives

• Reported a net loss of $53.5 million for the first quarter of 2026.
• Net loss per share was $0.30 for Q1 2026, compared to $0.42 for Q1 2025.
• Cash and cash equivalents decreased to $147.1 million as of March 31, 2026, from $182.5 million as of December 31, 2025.

Risks

• The inherent uncertainty of clinical drug development and the lengthy process for obtaining regulatory approvals.
• Risks related to the timely initiation and enrollment in clinical trials.
• Reliance on third parties, including Contract Research Organizations (CROs).
• Risks related to serious or undesirable side effects of therapeutic candidates.
• Risks related to the ability to utilize and protect intellectual property rights.
• Potential for future operating results to differ materially from forward-looking statements.
• Comparisons to efficacy results from other sponsors should be interpreted with caution due to differences in compounds, study designs, and subject characteristics.

Future Outlook

Neumora expects its cash and cash equivalents as of March 31, 2026, to fund its operating plan into the third quarter of 2027. The company anticipates a joint topline data readout for the navacaprant KOASTAL-2 and -3 studies in the second quarter of 2026. Data from the NMRA-511 MAD expansion cohort is expected in the second half of 2026, with a Phase 2 study planned for Q1 2027. Phase 1 data for NMRA-898 is also expected in the second half of 2026. NMRA-215 is expected to enter the clinic in Q1 2027, with a program update in H2 2026.

Management Comments

• "We focused on steady execution during the first quarter, highlighted by the full enrollment of the navacaprant KOASTAL2 and 3 studies with more than 400 patients per study. We look forward to the topline readout of these studies this quarter."
• "Additionally, we reported the Phase 1b study with NMRA-511 demonstrating an unsurpassed clinical effect in Alzheimers disease agitation and we remain on track to report data from the MAD expansion cohort in the second half of 2026, with a Phase 2 study anticipated to begin in the first quarter of 2027."
• "The Phase 1 study for NMRA898 is ongoing, with data expected in the second half of 2026, and we are advancing NMRA215, which is expected to enter the clinic in the first quarter of 2027, reflecting the breadth and continued momentum of our pipeline."
• "With a strong balance sheet, we believe we are well positioned to execute on these planned milestones and to continue progressing our portfolio in a disciplined manner."

Industry Context

StockSavvy.ai notes that Neumora Therapeutics' Q1 2026 update aligns with the broader biopharmaceutical industry's focus on advancing novel therapies for underserved neurological and psychiatric conditions. The company's progress in Alzheimer's disease agitation and major depressive disorder reflects significant investment and research in these challenging therapeutic areas.

Comparison to Industry Standards

• The reported net loss of $53.5 million for Q1 2026 is within the typical range for clinical-stage biopharmaceutical companies of Neumora's size, which often incur substantial R&D expenses without commensurate revenue.
• The cash runway extending into Q3 2027 is a critical positive, providing sufficient time to achieve key clinical milestones, a benchmark many early-stage biotechs strive for.
• The decrease in R&D and G&A expenses year-over-year, while maintaining pipeline momentum, suggests efficient operational management, a positive sign compared to companies struggling with cost control.

Stakeholder Impact

• Shareholders: Positive outlook due to pipeline advancement and extended cash runway, potentially leading to future value creation.
• Employees: Continued employment and potential for growth as the company progresses through clinical development.
• Creditors: The company's strong cash position provides comfort regarding its ability to meet financial obligations.

Next Steps

• Joint topline data readout for navacaprant KOASTAL-2 and -3 studies in Q2 2026.
• Report data from NMRA-511 MAD expansion cohort in H2 2026.
• Report data from NMRA-898 Phase 1 study in H2 2026.
• Provide program update for NMRA-215 in H2 2026.
• Initiate Phase 2 study for NMRA-511 in Q1 2027.
• Initiate NMRA-215 program in Q1 2027.

Key Dates

Recommendation

The filing indicates steady progress in clinical development and a solid cash position, which are positive. However, the company is still pre-revenue and faces significant clinical and regulatory risks. Therefore, a 'hold' recommendation is appropriate, pending further data readouts and de-risking of the pipeline.

Keywords

Neumora Therapeutics, 8-K, Financial Results, Clinical Stage Biopharmaceutical, Navacaprant, NMRA-511, NMRA-898, Alzheimer's Disease